- Details
- A new first-line standard of care -- JAVELIN Bladder 100 Platinum-based chemotherapy is currently the standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. In this Journal Club, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc review the JAVELIN Bladder 100 randomized, phase...
|
- Details
- Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc, discuss the recently published data (Lancet Oncology) from the CARD trial "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide." Previously reported from the CARD Study in the NEJM cabazitaxel significantly improved radiographic progression-free survival and o...
|
- Details
- In this Journal Club, Zachary Klaassen and Christopher Wallis present on the recently published New England Journal of Medicine article Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, data from the Phase 3 PROfound study. The primary outcome of the study was radiographic progression-free survival in cohort A, which was focused on BRCA1, BRCA2, and ATM mutant patients whi...
|
- Details
- Recently published in the Journal of Endourology and the Endourology Society, Jaime Landman, MD, talks with Roshan Patel, MD about his manuscript, titled “Uteroscopic Doppler Ultrasonography, Mapping Renal Blood Flow From Within the Collecting System.” Joined by Dr. Evangelos Liastikos, Dr. Patel notes that while ultrasound has been used in urology since the 1960s, there are limitations to the tec...
|
- Details
- Zachary Klaassen, MD, MSc, and Christorpher Wallis, MD, Ph.D., discuss the OLYMPUS study of using UGN-101, a mitomycin-containing reverse thermal gel, for the treatment of Upper Tract Urothelial Carcinoma. The Food and Drug Administration approved mitomycin for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). Efficacy determination was based on OLYMPUS, an ongoing, single-arm...
|
- Details
- In this Journal Club, Zachary Klaassen and Christopher Wallis review the recently published New England Journal of Medicine article Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, the double-blind, phase 3 PROSPER trial. Men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months)...
|
- Details
- Christopher Wallis and Zachary Klaassen host this journal club on "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," published by the HERO trial investigators in the New England Journal of Medicine simultaneously with the first presentation of the trial results at the ASCO 2020 annual meeting. Sharing background information on androgen deprivation therapy (ADT), as well...
|
- Details
- Recorded Date: April 24, 2020 Zachary Klaassen and Christopher Wallis join Alicia Morgans to discuss the management guidance released by European Urology on how to best optimize the care of patients with UTUC malignancies during the COVID-19 pandemic. In this Journal Club, Dr. Klaassen and Dr. Wallis assess the impact of delaying treatment in patients with upper tract urothelial carcinoma and disc...
|
- Details
- For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...
|
- Details
- Sia Daneshmand discusses a study published in European Urology which evaluated the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information. Biography: Siamak (Sia) Daneshmand,...
|
